Define the Role of POT1 Mutation in Genome Instability and Cancer

Information

  • Research Project
  • 10221642
  • ApplicationId
    10221642
  • Core Project Number
    U01CA231019
  • Full Project Number
    5U01CA231019-05
  • Serial Number
    231019
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    4/1/2021 - 3 years ago
  • Project End Date
    8/31/2023 - a year ago
  • Program Officer Name
    WITKIN, KEREN L
  • Budget Start Date
    9/1/2021 - 3 years ago
  • Budget End Date
    8/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
  • Award Notice Date
    9/8/2021 - 3 years ago

Define the Role of POT1 Mutation in Genome Instability and Cancer

Project Summary The goal of this proposal is to investigate the mechanism by which alteration in the telomere binding protein POT1 results in tumorigenesis. Mutations in POT1 (>100) have been associated with several types of human cancers such as chronic lymphocytic leukemia (CLL), cutaneous T cell lymphomas (CTCL), mantel cell lymphomas, parathyroid adenomas, gliomas, and melanomas. Our preliminary data indicate that perturbations in POT1 lead to replication stress at telomeres and telomere dysfunction. Moreover, we have shown that inhibition of POT1 in the common lymphoid progenitor cells (CLPs) promotes the formation of thymic lymphomas in mice. Here we will test our hypothesis that POT1 mutations trigger telomere replication stress which in turn leads to genome instability and cancer development. In addition, we will address the mechanism that enables cancer cells with POT1 mutations to bypass telomere replication stress and proliferate indefinitely. Lastly, we will develop a genetic screen to interrogate POT1 mutations in vivo and identify driver-mutations. In conclusion, our study will provide an important step towards identifying novel and effective therapeutic targets to treat an increasing number of cancer patients with POT1 mutations.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    239984
  • Indirect Cost Amount
    186680
  • Total Cost
    426664
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    393
  • Ed Inst. Type
  • Funding ICs
    NCI:426664\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    CE
  • Study Section Name
    Cancer Etiology Study Section
  • Organization Name
    SLOAN-KETTERING INST CAN RESEARCH
  • Organization Department
  • Organization DUNS
    064931884
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100656007
  • Organization District
    UNITED STATES